At Erasca, we've pivoted significantly, focusing on prioritizations and accessing capital to develop programs that genuinely impact patients.

The cancer-fighting community aims to increase the long-term remission rate from 20% to higher percentages by exploring various treatment combinations.

Our goal is to solve all diseases by leveraging AI to transform our understanding of biology and chemistry, enabling us to manipulate and craft solutions effectively.

We aim to create technologies and platform capabilities that are broadly useful, enabling new mechanistic insights and potentially curing diseases.

The future holds the potential to eradicate diseases, with nonprofits working to identify all human druggable targets to aid the drug industry.

Recent advancements in immunotherapy and targeted therapies are providing new hope in the fight against cancer, with exciting breakthroughs in treatments for various tumor types.

I aimed to build my company to deliver a product that could quickly provide answers for women with complex cysts, helping them avoid unnecessary interventions if they weren't cancerous.

We are conducting primary research on diseases related to aging, such as cancer and Parkinson's, through the Ellison Medical Foundation, and have invested around a billion dollars in this area.

We can significantly impact cancer prevention using polygenic risk scores and multi-cancer early detection tests that identify microscopic cancer.